<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38808863</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2150-1327</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Journal of primary care &amp; community health</Title><ISOAbbreviation>J Prim Care Community Health</ISOAbbreviation></Journal><ArticleTitle>Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs.</ArticleTitle><Pagination><StartPage>21501319241254751</StartPage><MedlinePgn>21501319241254751</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">21501319241254751</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/21501319241254751</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Over 30% of patients with COVID-19 have persistent symptoms that last beyond 30&#x2009;days and referred to as Long COVID. Long COVID has been associated with a persistent elevation in peripheral cytokines including interleukin-6, interleukin-1&#x3b2;, and tumor necrosis factor-&#x3b1;. This study reports cytokine profiles of patients in our clinic across SARS-COV-2 variant epochs.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The clinical cytokine panel was analyzed in patients with Long COVID during periods that were stratified according to variant epoch. The 4 variant epochs were defined as: (1) wild-type through alpha, (2) alpha/beta/gamma, (3) delta, and (4) omicron variants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 390 patients had the clinical cytokine panel performed; the median age was 48&#x2009;years (IQR 38-59) and 62% were female. Distribution by variant was wild-type and alpha, 50% (n&#x2009;=&#x2009;196); alpha/beta/gamma, 7.9% (n&#x2009;=&#x2009;31); delta, 18% (n&#x2009;=&#x2009;72); and omicron, 23% (n&#x2009;=&#x2009;91). Time to cytokine panel testing was significantly longer for the earlier epochs. Tumor necrosis factor-&#x3b1; (<i>P</i>&#x2009;&lt;&#x2009;.001) and interleukin 1&#x3b2; (<i>P</i>&#x2009;&lt;&#x2009;.001) were significantly more elevated in the earlier epochs (median of 558&#x2009;days in wild-type through Alpha epoch vs 263&#x2009;days in omicron epoch, <i>P</i>&#x2009;&lt;&#x2009;.001)). Nucleocapsid antibodies were consistently detected across epochs.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">When stratified by variant epoch, patients with early epoch Long COVID had persistently elevated peripheral pro-inflammatory cytokine levels when compared to later epoch Long COVID. Patients with Long COVID have similar clusters of symptoms across epochs, suggesting that the underlying pathology is independent of the peripheral cytokine signature.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ganesh</LastName><ForeName>Ravindra</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6877-1712</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Siddhant</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurt</LastName><ForeName>Ryan T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aakre</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilman</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grach</LastName><ForeName>Stephanie L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-8337-6219</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overgaard</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Melissa R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Nerissa M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croghan</LastName><ForeName>Ivana T</ForeName><Initials>IT</Initials><Identifier Source="ORCID">0000-0003-3464-3525</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badley</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razonable</LastName><ForeName>Raymund R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salonen</LastName><ForeName>Bradley R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI110173</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI120698</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI120698</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Prim Care Community Health</MedlineTA><NlmUniqueID>101518419</NlmUniqueID><ISSNLinking>2150-1319</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">variants</Keyword></KeywordList><CoiStatement>Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RG is a consultant for Alpaca Health; RTH is a consultant for Nestle; RG and RTH have received research funding from the GHR Foundation (Minneapolis, MN) and have received research support from electroCore Inc., InteraXon Inc., and Reulay Inc.; ADB is supported by grants from NIAID (grants AI110173 and AI120698), Amfar (#109593), and Mayo Clinic (HH Shieck Khalifa Bib Zayed Al-Nahyan Named Professorship of Infectious Diseases). ADB is a paid consultant for Abbvie, Gilead, Freedom Tunnel, Pinetree therapeutics Primmune, Immunome, MarPam, Rion, Symbiosis, NexImmune and Flambeau Diagnostics, is a paid member of the DSMB for Corvus Pharmaceuticals, Equilium, CSL Behring, and Excision Biotherapeutics. Raymund R. Razonable has received grants from Regeneron, Roche, and Gilead for research not directly related to this study. All authors are employees of the Mayo Clinic. All other authors report no potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>29</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>29</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>29</Day><Hour>8</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38808863</ArticleId><ArticleId IdType="pmc">PMC11138192</ArticleId><ArticleId IdType="doi">10.1177/21501319241254751</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization. WHO COVID-19 Dashboard. World Health Organization. 2021. Accessed July 27, 2023. https://covid19.who.int/</Citation></Reference><Reference><Citation>Zheng M, Gao Y, Wang G, et al.. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533-535. doi:10.1038/s41423-020-0402-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0402-2</ArticleId><ArticleId IdType="pmc">PMC7091858</ArticleId><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Talukder A, Razu SR, Alif SM, Rahman MA, Islam SMS. Association between symptoms and severity of disease in hospitalised novel coronavirus (COVID-19) patients: a systematic review and meta-analysis. J Multidiscip Healthc. 2022;15:1101-1110. doi:10.2147/JMDH.S357867</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JMDH.S357867</ArticleId><ArticleId IdType="pmc">PMC9113266</ArticleId><ArticleId IdType="pubmed">35592814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson JG, Simpson LJ, Ferreira AM, et al.. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. 2020;5(17):e140289. doi:10.1172/jci.insight.140289</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140289</ArticleId><ArticleId IdType="pmc">PMC7526438</ArticleId><ArticleId IdType="pubmed">32706339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh R, Grach SL, Ghosh AK, et al.. The female-predominant persistent immune dysregulation of the post-COVID syndrome. Mayo Clin Proc. 2022;97(3):454-464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8817110</ArticleId><ArticleId IdType="pubmed">35135695</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Ma Q, Li C, et al.. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123-1130. doi:10.1080/22221751.2020.1770129</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q, Wang B, Mao J. The pathogenesis and treatment of the; Cytokine Storm&#x2019; in COVID-19. J Infect. 2020;80(6):607-613. doi:10.1016/j.jinf.2020.03.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.037</ArticleId><ArticleId IdType="pmc">PMC7194613</ArticleId><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, Paschold L, Willscher E, et al.. Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19. iScience. 2021;24(11):103325. doi:10.1016/j.isci.2021.103325</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103325</ArticleId><ArticleId IdType="pmc">PMC8536484</ArticleId><ArticleId IdType="pubmed">34723157</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M, Ramonell R, Cashman K, et al.. Dominant extrafollicular B cell responses in severe COVID-19 disease correlate with robust viral-specific antibody production but poor clinical outcomes. Posted online June 22, 2020. medRxiv. doi:10.1101/2020.04.29.20083717</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.29.20083717</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi MO, Beltagy A, Garrafa E, et al.. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol. 2020;11:584241. doi:10.3389/fimmu.2020.584241</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.584241</ArticleId><ArticleId IdType="pmc">PMC7593765</ArticleId><ArticleId IdType="pubmed">33178218</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al.. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661-1663. doi:10.1136/annrheumdis-2020-218009</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218009</ArticleId><ArticleId IdType="pubmed">32581086</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al.. Diverse functional autoantibodies in patients with COVID-19. Posted online February 1, 2021. medRxiv. doi:10.1101/2020.12.10.20247205</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.10.20247205</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Estes SK, Ali RA, et al.. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876. doi:10.1126/scitranslmed.abd3876</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Hsu AC, Pang Z, et al.. Role of the innate cytokine storm induced by the influenza A virus. Viral Immunol. 2019;32(6):244-251. doi:10.1089/vim.2019.0032</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2019.0032</ArticleId><ArticleId IdType="pubmed">31188076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol. 2007;147(2):227-235. doi:10.1111/j.1365-2249.2006.03261.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2006.03261.x</ArticleId><ArticleId IdType="pmc">PMC1810472</ArticleId><ArticleId IdType="pubmed">17223962</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009;227(1):75-86. doi:10.1111/j.1600-065X.2008.00737.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2008.00737.x</ArticleId><ArticleId IdType="pmc">PMC5489343</ArticleId><ArticleId IdType="pubmed">19120477</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605. doi:10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, et al.. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4-e6. doi:10.1016/j.jinf.2020.08.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi:10.1136/bmj.m3026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladds E, Rushforth A, Wieringa S, et al.. Persistent symptoms after Covid-19: qualitative study of 114 &#x201c;long Covid&#x201d; patients and draft quality principles for services. BMC Health Serv Res. 2020;20(1):1144. doi:10.1186/s12913-020-06001-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-020-06001-y</ArticleId><ArticleId IdType="pmc">PMC7750006</ArticleId><ArticleId IdType="pubmed">33342437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladds E, Rushforth A, Wieringa S, et al.. Developing services for long COVID: lessons from a study of wounded healers. Clin Med (Lond). 2021;21(1):59-65. doi:10.7861/clinmed.2020-0962</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0962</ArticleId><ArticleId IdType="pmc">PMC7850205</ArticleId><ArticleId IdType="pubmed">33479069</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al.. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021;4(2):e210830. doi:10.1001/jamanetworkopen.2021.0830</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, et al.. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. doi:10.1371/journal.pone.0240784</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A, et al.. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun. 2022;13(1):5663. doi:10.1038/s41467-022-33415-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33415-5</ArticleId><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, et al.. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604-1615. doi:10.1001/jama.2022.18931</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, et al.. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529. doi:10.1136/bmj-2022-072529</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Agergaard J, Gunst JD, Schi&#xf8;ttz-Christensen B, &#xd8;stergaard L, Wejse C. Long-term prognosis at 1.5 years after infection with wild-type strain of SARS-CoV-2 and Alpha, Delta, as well as Omicron variants. Int J Infect Dis. 2023;137:126-133. doi:10.1016/j.ijid.2023.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.10.022</ArticleId><ArticleId IdType="pubmed">37907167</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, et al.. From online data collection to identification of disease mechanisms: the IL-1&#xdf;, IL-6 and TNF-&#x3b1; cytokine triad is associated with post-acute sequelae of COVID-19 in a digital research cohort. SSRN Electronic Journal. 2021. doi:10.2139/ssrn.3963839</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3963839</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, Willscher E, Paschold L, et al.. The IL-1beta, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022;3(6):100663. doi:10.1016/j.xcrm.2022.100663</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz MAF, Neves P, Lima SS, et al.. Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome. Front Cell Infect Microbiol. 2022;12:922422. doi:10.3389/fcimb.2022.922422</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Croghan C, Egeghy PP. Methods of dealing with values below the limit of detection using SAS. Southern SAS User Group. 2003;22:24.</Citation></Reference><Reference><Citation>O&#x2019;Horo JC, Challener DW, Speicher L, et al.. Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the delta variant. Mayo Clin Proc. 2022;97(2):327-332. doi:10.1016/j.mayocp.2021.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.12.002</ArticleId><ArticleId IdType="pmc">PMC8674496</ArticleId><ArticleId IdType="pubmed">35120695</ArticleId></ArticleIdList></Reference><Reference><Citation>Razonable RR, O&#x2019;Horo JC, Hanson SN, et al.. Comparable outcomes for bebtelovimab and ritonavir-boosted nirmatrelvir treatment in high-risk patients with coronavirus disease-2019 during severe acute respiratory syndrome coronavirus 2 BA.2 omicron epoch. J Infect Dis. 2022;226(10):1683-1687. doi:10.1093/infdis/jiac346</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac346</ArticleId><ArticleId IdType="pmc">PMC9494486</ArticleId><ArticleId IdType="pubmed">36124696</ArticleId></ArticleIdList></Reference><Reference><Citation>Razonable RR, Tulledge-Scheitel SM, Hanson SN, et al.. Real-world clinical outcomes of bebtelovimab and sotrovimab treatment of high-risk persons with coronavirus disease 2019 during the omicron epoch. Open Forum Infect Dis. 2022;9(10):ofac411. doi:10.1093/ofid/ofac411</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac411</ArticleId><ArticleId IdType="pmc">PMC9536189</ArticleId><ArticleId IdType="pubmed">36213724</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnostics R. Elecsys anti-SARS-CoV-2. US FAD-EUA. 2020;5:2.</Citation></Reference><Reference><Citation>Ganesh R, Ghosh AK, Nyman MA, et al.. PROMIS scales for assessment of persistent post-COVID symptoms: a cross sectional study. J Prim Care Community Health. 2021;12:21501327211030413. doi:10.1177/21501327211030413</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21501327211030413</ArticleId><ArticleId IdType="pmc">PMC8267017</ArticleId><ArticleId IdType="pubmed">34231395</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh R, Vanichkachorn GS, Munipalli B, et al.. Postacute sequelae of SARS-CoV-2 infection-lessons learned from a coordinated health system response. Mayo Clin Proc Innov Qual Outcomes. 2022;6(4):311-319. doi:10.1016/j.mayocpiqo.2022.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocpiqo.2022.05.007</ArticleId><ArticleId IdType="pmc">PMC9156955</ArticleId><ArticleId IdType="pubmed">35669936</ArticleId></ArticleIdList></Reference><Reference><Citation>Fertleman M, Pereira C, Dani M, Harris BHL, Di Giovannantonio M, Taylor-Robinson SD. Cytokine changes in cerebrospinal fluid and plasma after emergency orthopaedic surgery. Sci Rep. 2022;12(1):2221. doi:10.1038/s41598-022-06034-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-06034-9</ArticleId><ArticleId IdType="pmc">PMC8828833</ArticleId><ArticleId IdType="pubmed">35140282</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison VJ, Mocatta TJ, Winterbourn CC, Darlow BA, Volpe JJ, Inder TE. The relationship of CSF and plasma cytokine levels to cerebral white matter injury in the premature newborn. Pediatr Res. 2005;57(2):282-286. doi:10.1203/01.Pdr.0000148286.53572.95</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/01.Pdr.0000148286.53572.95</ArticleId><ArticleId IdType="pubmed">15585689</ArticleId></ArticleIdList></Reference><Reference><Citation>Grach SL, Ganesh R, Messina SA, Hurt RT. Post-COVID-19 syndrome: persistent neuroimaging changes and symptoms 9 months after initial infection. BMJ Case Rep. 2022;15(4):e248448. doi:10.1136/bcr-2021-248448</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-248448</ArticleId><ArticleId IdType="pmc">PMC8996041</ArticleId><ArticleId IdType="pubmed">35396239</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, et al.. (18)F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48(9):2823-2833. doi:10.1007/s00259-021-05215-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand A, Campion JY, Lepine A, et al.. Similar patterns of [(18)F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series. Eur J Nucl Med Mol Imaging. 2021;49:913-920. doi:10.1007/s00259-021-05528-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05528-4</ArticleId><ArticleId IdType="pmc">PMC8376118</ArticleId><ArticleId IdType="pubmed">34414470</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser D, Golla SSV, Verfaillie SCJ, et al.. Long COVID is associated with extensive in-vivo neuroinflammation on [18F]DPA-714 PET. Posted online June 4, 2022. medRxiv. 2022. doi:10.1101/2022.06.02.22275916</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.02.22275916</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshelh Z, Albrecht DS, Bergan C, et al.. In-vivo imaging of neuroinflammation in veterans with Gulf War illness. Brain Behav Immun. 2020;87:498-507. doi:10.1016/j.bbi.2020.01.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.01.020</ArticleId><ArticleId IdType="pmc">PMC7864588</ArticleId><ArticleId IdType="pubmed">32027960</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, et al.. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022;21(1):148. doi:10.1186/s12933-022-01579-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01579-5</ArticleId><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, et al.. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. doi:10.1186/s12933-021-01359-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al.. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76(3):e487-e490. doi:10.1093/cid/ciac722</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A, Vecchi&#xe9; A, Dagna L, et al.. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021;21(5):319-329. doi:10.1038/s41577-021-00536-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00536-9</ArticleId><ArticleId IdType="pmc">PMC8023349</ArticleId><ArticleId IdType="pubmed">33824483</ArticleId></ArticleIdList></Reference><Reference><Citation>Krutikov M, Palmer T, Tut G, et al.. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. Lancet Healthy Longev. 2022;3(1):e13-e21. doi:10.1016/S2666-7568(21)00282-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(21)00282-8</ArticleId><ArticleId IdType="pmc">PMC8676418</ArticleId><ArticleId IdType="pubmed">34935001</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Elslande J, Oyaert M, Ailliet S, et al.. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. J Clin Virol. 2021;136:104765. doi:10.1016/j.jcv.2021.104765</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2021.104765</ArticleId><ArticleId IdType="pmc">PMC7891078</ArticleId><ArticleId IdType="pubmed">33636554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ES, Jeon MT, Kim KS, Lee S, Kim S, Kim DG. Spike proteins of SARS-CoV-2 induce pathological changes in molecular delivery and metabolic function in the brain endothelial cells. Viruses. 2021;13(10):2021. doi:10.3390/v13102021</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13102021</ArticleId><ArticleId IdType="pmc">PMC8538996</ArticleId><ArticleId IdType="pubmed">34696455</ArticleId></ArticleIdList></Reference><Reference><Citation>DeOre BJ, Tran KA, Andrews AM, Ramirez SH, Galie PA. SARS-CoV-2 spike protein disrupts blood-brain barrier integrity via RhoA activation. J Neuroimmune Pharmacol. 2021;16(4):722-728. doi:10.1007/s11481-021-10029-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-021-10029-0</ArticleId><ArticleId IdType="pmc">PMC8536479</ArticleId><ArticleId IdType="pubmed">34687399</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Yang W, Chen F, Cui L. COVID-19 and cognitive impairment: neuroinvasive and blood-brain barrier dysfunction. J Neuroinflammation. 2022;19(1):222. doi:10.1186/s12974-022-02579-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02579-8</ArticleId><ArticleId IdType="pmc">PMC9450840</ArticleId><ArticleId IdType="pubmed">36071466</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, et al.. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758-763. doi:10.1038/s41586-022-05542-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH, Perl DP, Steiner J, et al.. Neurovascular injury with complement activation and inflammation in COVID-19. Brain. 2022;145(7):2555-2568. doi:10.1093/brain/awac151</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac151</ArticleId><ArticleId IdType="pmc">PMC9278212</ArticleId><ArticleId IdType="pubmed">35788639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH, Perl DP, Nair G, et al.. Microvascular injury in the brains of patients with Covid-19. N Engl J Med. 2021;384(5):481-483. doi:10.1056/NEJMc2033369</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2033369</ArticleId><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo R, Trimarco V, Mone P, et al.. Combining L-arginine with vitamin C improves long-COVID symptoms: the LINCOLN Survey. Pharmacol Res. 2022;183:106360. doi:10.1016/j.phrs.2022.106360</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106360</ArticleId><ArticleId IdType="pmc">PMC9295384</ArticleId><ArticleId IdType="pubmed">35868478</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosato M, Calvani R, Picca A, et al.. Effects of l-arginine plus vitamin C supplementation on physical performance, endothelial function, and persistent fatigue in adults with long COVID: a single-blind randomized controlled trial. Nutrients. 2022;14(23):4984. doi:10.3390/nu14234984</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14234984</ArticleId><ArticleId IdType="pmc">PMC9738241</ArticleId><ArticleId IdType="pubmed">36501014</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei S, Gholamalizadeh M, Tabrizi R, Nowrouzi-Sohrabi P, Rastgoo S, Doaei S. The effect of L-arginine supplementation on maximal oxygen uptake: a systematic review and meta-analysis. Physiol Rep. 2021;9(3):e14739. doi:10.14814/phy2.14739</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14739</ArticleId><ArticleId IdType="pmc">PMC7883807</ArticleId><ArticleId IdType="pubmed">33587327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambardella J, Khondkar W, Morelli MB, Wang X, Santulli G, Trimarco V. Arginine and endothelial function. Biomedicines. 2020;8(8):277. doi:10.3390/biomedicines8080277</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8080277</ArticleId><ArticleId IdType="pmc">PMC7460461</ArticleId><ArticleId IdType="pubmed">32781796</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar S, Kabat J, Jerome K, Feldmann F, Bailey K, Mehedi M. Nuclear translocation of spike mRNA and protein is a novel pathogenic feature of SARS-CoV-2. Posted online September 27, 2022. bioRxiv. doi:10.1101/2022.09.27.509633</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.09.27.509633</ArticleId><ArticleId IdType="pmc">PMC9909199</ArticleId><ArticleId IdType="pubmed">36778849</ArticleId></ArticleIdList></Reference><Reference><Citation>Crunfli F, Carregari VC, Veras FP, et al.. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci USA. 2022;119(35):e2200960119. doi:10.1073/pnas.2200960119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2200960119</ArticleId><ArticleId IdType="pmc">PMC9436354</ArticleId><ArticleId IdType="pubmed">35951647</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhea EM, Logsdon AF, Hansen KM, et al.. The S1 protein of SARS-CoV-2 crosses the blood&#x2013;brain barrier in mice. Nat Neurosci. 2021;24(3):368-378. doi:10.1038/s41593-020-00771-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00771-8</ArticleId><ArticleId IdType="pmc">PMC8793077</ArticleId><ArticleId IdType="pubmed">33328624</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy S, Reddy S, Arora M. A case of postural orthostatic tachycardia syndrome secondary to the messenger RNA COVID-19 vaccine. Cureus. 2021;13(5):e14837. doi:10.7759/cureus.14837</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.14837</ArticleId><ArticleId IdType="pmc">PMC8101507</ArticleId><ArticleId IdType="pubmed">33968543</ArticleId></ArticleIdList></Reference><Reference><Citation>Potential POTS association with COVID-19 vaccination weaker than with COVID-19 infection. Nat Cardiovasc Res. 2022;1(12):1132-1133. doi:10.1038/s44161-022-00194-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44161-022-00194-7</ArticleId><ArticleId IdType="pmc">PMC9748890</ArticleId><ArticleId IdType="pubmed">36530759</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC. COVID data tracker. CDC. Accessed July 27, 2023. https://covid.cdc.gov/covid-data-tracker/#variant-proportions</Citation></Reference><Reference><Citation>Brook B, Fatou B, Checkervarty A, et al.. The mRNA vaccine BNT162b2 demonstrates impaired TH1 immunogenicity in human elders in vitro and aged mice in vivo. Res Sq. 2022; rs.3.Rs-2395118. doi:10.21203/rs.3.rs-2395118/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-2395118/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al.. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27(2):270-278. doi:10.1038/s41591-020-01194-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01194-5</ArticleId><ArticleId IdType="pubmed">33335323</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M, Rabaan AA, Alwarthan S, et al.. Regulatory T cells (tregs) and COVID-19: unveiling the mechanisms, and therapeutic potentialities with a special focus on long COVID. Vaccines (Basel). 2023;11(3):699. doi:10.3390/vaccines11030699</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030699</ArticleId><ArticleId IdType="pmc">PMC10059134</ArticleId><ArticleId IdType="pubmed">36992283</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>